YearImpact Factor (IF)Total ArticlesTotal Cites 2023 (2024 update)4.8-- 20226.4-4880 20215.854-4649 20205.9871633768 20194.534432914 20184.681322842 20174.044562928 20163.652632756 20152.532742605 20142.416672501 20132.553912656 20122.9451062700 20112.802912486 20103.744913028 <<Cancer Epidemiology Cancer Genetics and Cytogenetics>>
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.
17 July 2024|Open Access MethNet: a robust approach to identify regulatory hubs and their distal targets from cancer data Epigenetic aberrations can affect gene regulation and impact diseases, but understanding these regulatory connections remains challenging. Here, the authors present MethNet, a pipeli...
Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy. Year Impact Factor (IF) Total Articles Total Cites 2023 (2024 update) 2.4 - - 2022 3.2 - 16460 2021 3.838 - 17993 2020 3.167 560 16078 ...
19 June 2024 Clinical/translational cancer immunotherapy: Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer 23 October 2024 Immune cell therapies and immune cell engineering: ...
node-positive early luminal breast cancer. The WSG-PRIMe study has prospectively demonstrated the impact of MammaPrint®and BluePrint on treatment decision [49]. BluePrint is an 80-gene assay that allows a molecular sub-classification into low-risk luminal tumors, high-risk luminal tumors, HER2...
New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially ...
Article Open access 25 January 2024 1 Introduction Pancreatic cancer is one of the most lethal malignancies, ranking as the fourth leading cause of cancer-related mortality [1]. Pancreatic ductal adenocarcinoma (PDAC) comprises more than 95% of PC [2]. PC still remains a deadly malignancy with...
A Phase II study of osimertinib in patients with advanced stage non-small cell lung cancer following prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy with EGFR and T790M Mutations detected in plasma circulating tumour DNA (PLASMA study) ...
2024, Cancer Cell Citation Excerpt : And those genes with a q-value <0.01 were considered as significantly changed genes and were identified by the differential GeneTest function in Monocle2. The normal fibroblasts were defined as those with high expression of previously reported specific markers, ...